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Case presentation
A 74-year-old man with a history of peptic ulcer disease arrived at the
hospital complaining of persistent midepigastric pain that had lasted 3
days but which had worsened over the previous 24 hours. Because he
was nauseated, he had taken little by mouth except ginger ale over the
2 days prior to admission. Physical examination revealed a temperature
of 99.rF, an orthostatic blood pressure drop from 120/82mm Hg lying
to 90/58 mm Hg standing, and an orthostatic pulse rate elevation from
90/minto 120/mm. He had abdominal tenderness without rebound in the
midepigastrium. Laboratory data disclosed BUN, 40 mg/dl; serum
creatinine, 1.8 mgldl; and amylase, 190 Somogyi units/dI (normal,
80—200 units). Urinalysis was normal and examination of a random
urine collection revealed a sodium concentration of 4 mEq/liter, urine
osmolality of 750 mOsm/kg HO, and FEN., of 0.4c.
The patient was treated with intravenous fluids and nasogastric
suction. Six hours after admission, he developed severe midepigastric
pain with rebound tenderness and a temperature of l02.5F. The clinical
diagnosis of perforated peptic ulcer was confirmed at operation and an
exploratory taparotomy was done. Immediately postoperatively, the
BUN was 28 mg/dI and serum creatinine 1.4 mg/dl. The patient was
given clindamycin, 500 mg every 6 hours, and gentarnicin. 80 mg every
8 hours. Three days later, blood cultures grew Pseudomonas aerugi-
nosa sensitive to gentamicin and tobramycin. Both antibiotics were
continued. The patient stabilized and improved, maintaining a urine
output of 1500 mI/day. Six days after operation. laboratory studies
revealed a BUN of 30 mg/dl and a serum creatinine of 2.7 mg/dl; no
BUN and creatinine determinations had been done in the interval.
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Urinalysis showed granular casts and a substantial number of renal
epithelial cells. Urine sodium concentration was now 45 mEq/liter;
urine osmolality, 300 mOsm/kg H,O; and urine FEN., 1.8%. At that
time, peak and trough serum gentamicin concentrations were 15 sg/ml
and 5 g/ml, respectively. The..gentamicin dose was reduced to 70 mg
every 24 hours, but serum creatinine continued to rise slowly over the
next 4 days to 5.7 mg/dl despite appropriate dosing adjustments to
maintain peak and trough levels below toxic serum levels. After 10
days, gentamicin therapy was discontinued, but the patient's serum
creatinine rose to a maximal value of 7.8 mg'dl on day 14. At no time did
the patient develop hyperkalemia, fluid overload, or uremic symptoms.
The serum creatinine persisted at 7.8 mg/dl until day 17. when it began
to decline; ultimately it reached a level of 1.2 mg/dl on the 28th day after
the patient was discharged from the hospital.
Discussion
DR. H. DAVID HUMES (Chief, Medical Service, Veterans
Administration Medical Center; and Professor and Associate
Chairman, Department of Internal Medicine, Unii'ersitv of
Michigan Medical Center, Ann Arbor, Michigan): Aminoglyco-
side antibiotics, despite their nephrotoxicity, continue to be a
mainstay in the clinical management of gram-negative infec-
tions. Gram-negative organisms account for the majority of
hospital-acquired infections [I], and the occurrence of amino-
glycoside-induced acute renal failure remains cdmmonplace. A
recent prospective study of hospital-acquired acute renal failure
in 2116 patients revealed that 11% of the cases probably were
related to aminoglycoside use [2]. in a variety of clinical
studies, the use of gentamicin has been associated with acute
renal failure in 8% to 26% of patients [3]. The understanding of
aminoglycoside nephrotoxicity therefore has substantial clinical
relevance. In this Forum, I will summarize the renal handling of
the aminoglycosides, the pathogenetic mechanisms of nephro-
toxicity, and the clinical aspects of aminoglycoside-induced
acute renal failure. I will place particular emphasis on recent
data that have increased our understanding of the interaction of
aminoglycosides with the renal tubular cell and the effects of
this interaction on cellular function and integrity.
Renal handling of aminoglycosides
Most experimental evidence indicates that net reabsorption
of aminoglycosides occurs in the proximal tubule by means of a
high-capacity transport system [4. 5]. Little direct evidence
supports increases in luminal concentration of aminoglycosides
along the proximal tubule. Net drug secretion might occur in the
early proximal tubule at high doses, whereas net secretion in
the late proximal tubule ol' juxtamedullary nephrons might
occur at lower doses [5]. This nephronal heterogeneity in drug
handling explains most features observed in the experimental
setting, and I will discuss these later.
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Roth luminal reabsorption and basolateral uptake probably
account for the high drug levels achieved in renal cortical tissue
in experimental animals and in humans; variability in these
processes, in turn, accounts for the variations in cortical drug
content noted among different aminoglycosides [6]. Luminal
drug uptake occurs after aminoglycoside binding to brush-
border membrane sites and is followed by absorptive pinocyto-
sis, the dominant pathway for intracellular drug accumulation
[7]. Drug uptake is followed by lysosomal processing, although
temporal and quantitative evidence suggests important interac-
tions with other intracellular organelles [8]. After being taken
up by the renal tubular cell, aminoglycosides reside in a poorly
exchangeable pool; they therefore have prolonged tissue half-
lives [9].
Aminoglycosides produce tubular cell necrosis, which is
largely confined to the proximal convoluted tubule and pars
recta [10, 11]. The earliest lesion, seen by electron microscopy,
is an increase in the number and size of secondary lysosomes
(cystosegrosomes, phagosomes) [10]. The development of ly-
sosomal alterations during aminoglycoside administration does
not necessarily progress to renal cell necrosis and organ failure,
however [12]. Additionally, these morphologic alterations are
not specific for aminoglycoside toxicity and can occur in other
tissues alter focal cell injury induced by a variety of toxins [13].
Following lysosomal injury, injury to renal proximal tubule
cells continues, as reflected by mitochondrial swelling and
increasing loss of brush-border membranes. The degree of cell
injury in the proximal tubule correlates reasonably well with the
decline in renal excretory function. The pattern of substantial
involvement of S1 and S2 proximal tubular segments in amino-
glycoside injury contrasts with the markedly greater involve-
ment of the S3 segments in heavy-metal nephrotoxicity and
ischemia. Perhaps this difference is due to a much higher toxin
load presented to the more proximal S1 and S2 cells along the
tubule. Distal tubules and glomeruli reveal little damage by light
and transmission electron microscopy [10, 14].
Regeneration of proximal tubule cells begins during the stage
of patchy necrosis. The relatively undifferentiated, immature,
regenerating cells subsequently begin to regain normal height
and structure. Foci of interstitial inflammatory infiltrates appear
throughout the cortex during this stage and can become more
prominent with time [15]. Eventually, most areas of the affected
kidney regain normal architecture and function, but residual
scars containing collapsed, atrophic tubules can develop in the
cortex [16]. 1 should note the interesting fact that regeneration
can continue within the renal cortex even in the presence of
continued aminoglycoside administration and toxic drug levels
in the renal cortex [17].
Aminoglycoside nephrotoxicity is characterized by a variety
of renal functional alterations. Renal excretory failure with near
cessation of effective glomerular filtration rate is but the final
manifestation of this clinical disorder. Prior to this evenL more
subtle nephronal derangements, dominated by proximal tubular
abnormalities, occur in humans and animals.
The initial renal manifestation of aminoglycoside toxicity is
enzymuria. As early as 24 hours after a single therapeutic dose
of aminoglycoside, the urinary excretion of a variety of brush-
border membrane enzymes increases and progressively rises as
therapy continues [18]. Increases in the urinary excretion of
various lysosomal enzymes also can be seen.
Table I. Risk factors in aminoglycoside nephrotoxicity
1. Dose and duration of drug treatment
2. Recent aminoglycoside therapy
3. Preexisting renal insufficiency
4. Preexisting hepatic disease
5. Elderly age
6. Concomitant nephrotoxic drug administration
7. Volume depletion
8. Potassium depletion
9. Magnesium depletion
Proximal tubular transport processes also deteriorate during
aminoglycoside toxicity. This alteration results in glycosuria,
aminoaciduria, tubular proteinuria, and transport defects con-
sistent with a Fanconi-like syndrome [13]. Aminoglycosides
also can induce renal potassium and magnesium wasting, with
resulting hypokalemia and hypomagnesemia [15]. The selective
effects on the renal handling of these intracellular cations may
reflect a specificity of action of the aminoglycosides. namely,
alteration of plasma membrane transport of, or permeability to,
these particular ions.
Polyuria and nephrogenic diabetes insipidus develop early in
aminoglycoside nephrotoxicity [15]. Urinary concentrating de-
fects and resistance to antidiuretic hormone characterize most
states of tubulointerstitial injury and are due, in large part, to an
inability of the injured kidney to maintain the hypertonicity of
the medullary interstitium. For the aminoglycosides, inhibition
of antidiuretic hormone activity (via interference with the
action of adenylate cyclase) may be an additional pathogenetic
cause for this functional defect [19].
A variety of factors predispose to aminoglycoside nephrotox-
icity (Table I). The dose and duration of drug administration are
the two most important. Higher antibiotic doses result in higher
serum drug levels and more rapid aminoglycoside accumulation
in the kidney. Prolonged therapy increases the risk that toxic
concentrations will persist within renal parenchyma. A relation-
ship between serum levels, renal parenchymal concentration,
and nephrotoxicity for any given aminoglycoside has been
suggested [20, 21]. The risk of aminoglycoside toxicity is
increased not only in patients given continuous prolonged
therapy, but also in those given the drug in repeated courses
separated by a few days or weeks.
The probability that a given patient will develop nephrotox-
icity when given an aminoglycoside is increased by several
factors including (1) increasing age, (2) preexisting renal insuf-
ficiency [22], (3) concomitant administration of intrinsically
nephrotoxic agents (such as cyclosporine [23]), (4) preexisting
liver disease, (5) severe hypertension [24], and (6) fluid and
electrolye abnormalities. Volume depletion potentiates nephro-
toxicity, presumably because of elevated rates of aminoglyco-
side accumulation in the renal cortex [25]. In experimental
animals, potassium depletion condenses the usual time frame
for aminoglycoside-induced acute renal failure [26]. Finally,
gentamicin nephrotoxicity is potentiated by magnesium deple-
tion [27].
Diagnosis' and treatment
Aminoglycoside nephrotoxicity typically is associated with
nonoliguric acute renal failure, that is, azotemia in the presence
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of urine output between 1 and 2 liters/day. Urine output is,
therefore, an unreliable marker for the development of amino-
glycoside nephrotoxicity. Declines in glomerular filtration rate
and elevations in serum creatinine usually are not apparent until
after 7 to 10 days of aminoglycoside treatment. However, the
presence of any of the risk factors I mentioned can condense
this time frame. Before concluding that a patient has nephro-
toxic acute renal failure, or aminoglycoside-induced acute renal
failure, in particular, reversible prerenal and postrenal causes
must be excluded.
When using these potentially life-saving antibiotics, we are
faced with competing goals: on the one hand we want to achieve
high peak and mean plasma aminoglycoside levels during
treatment to eliminate the invading bacteria [28] and, on the
other hand, we want to avoid nephrotoxicity. Unfortunately,
effective therapeutic doses for antibacterial activity are very
near potentially toxic doses. Because many factors such as
renal function, age, and sodium balance can affect serum levels
of the aminoglycosides, assays monitoring antibiotic levels are
required to maintain effective but nontoxic antibacterial con-
centrations. Avoidance of peak serum concentrations of genta-
micin or tobramycin greater than 10 g/ml and trough serum
concentrations greater than 2 jig/mI have been associated with
lower rates of nephrotoxicity [21]. Undue emphasis on the
trough aminoglycoside level may be inappropriate, however,
because elevations of trough serum aminoglycoside levels fre-
quently are the result, not the cause, of renal insufficiency [29].
Various formulas have been devised for calculating dose alter-
ations in the presence of renal insufficiency so that serum drug
levels can be maintained below these toxic concentrations.
These formulas provide only an approximation of the appropri-
ate dose. Serum level monitoring must be employed to ensure a
correct dosing schedule given the multiple factors besides renal
function that can influence antibiotic excretion, serum levels,
and renal accumulation. These final adjustments in dose, based
on serum antibiotic concentrations, are especially necessary in
the elderly, in. whom serum creatinine is not as accurate a
reflection of renal function as in younger patients.
Every effort should be made to avoid those factors known to
provoke toxicity. The patient receiving an aminoglycoside
should be well hydrated to avoid volume depletion, and should
be potassium and magnesium replete, especially in the clinical
settings requiring concurrent treatment with potent diuretic
agents. Finally, if therapy was begun empirically, continuation
of aminoglycoside therapy should be based on the results of
bacterial cultures. If the serum creatinine rises and glomerular
filtration rate declines, one should consider discontinuation of
the aminoglycoside if a different, but equally efficacious, anti-
biotic can be substituted. If the aminoglycoside must be con-
tinued in the presence of developing acute renal failure, the only
reliable guide to proper dosage is the serum drug level. Even if
the antibiotic is discontinued at the time the serum creatinine
begins to rise, renal injury can continue and can be followed by
severe acute renal failure. This phenomenon also occurs regu-
larly in the animal models of gentamicin nephrotoxicity and
likely reflects the continued effects of the accumulation of high
antibiotic levels in tissue. Because even a modest decline in
glomerular filtration rate can be a signal of progressive renal
damage, there is a premium on recognizing incipient renal
damage. To do so, daily assessment of renal function is essen-
tial. Once established, aminoglycoside-induced acute renal fail-
ure must be handled like any other type of acute renal failure,
with careful fluid and electrolyte management and, if necessary,
dialysis.
Co,nparafive clinical nephrotox:city
The comparative nephrotoxicity of the aminoglycosides has
been established for gentamicin, tobramycin, amikacin, and
netilmicin [131. Inferences concerning clinical toxicity based on
animal studies, however, must be made with caution, because
both the onset and severity of aminoglycoside nephrotoxicity
depend on the species and strain of experimental animal uti-
lized, gender, age, and dosing schedule [13].
The many clinical studies of aminoglycoside toxicity have
been the subject of a recent review that analyzed 144 published
trials involving nearly 10,000 patients [30]. The findings under-
score the difficulty inherent in comparing relative drug nephro-
toxicities among studies. The incidence of nephrotoxicity in
prospective comparative trials varies considerably, thus em-
phasizing the need for rigorously defined nephrotoxicity crite-
ria, patient randomization, concurrent controls, and double-
blind evaluations. Overall, gentamicin and tobramycin appear
to be equally nephrotoxic and are slightly more nephrotoxic
than are amikacin and netilmicin; amikacin and netilmicin
appear to be equally nephrotoxic. When prospective compara-
tive trials are considered separately, gentamicin appears to be
the most nephrotoxic drug, followed in order of decreasing
nephrotoxicity by tobramycin, amikacin, and netilmicin. It is
interesting yet unexplained why the incidence of gentamicin
nephrotoxicity is greater in trials comparing the drug with
netilmicin than in those comparing gentamicin with other ami-
noglycosides. Further, in a comparative trial with tobramycin,
gentamicin appeared to be more nephrotoxic than in an earlier
comparative trial with amikacin, even though the studies were
undertaken by the same group of investigators using similar
criteria [29].
These studies have prompted several suggestions regarding
aminoglycoside administration in older patients and in those
with preexisting renal insufficiency or liver disease. Because
these patients are at greater risk of toxicity, tobramycin rather
than gentamicin is a reasonable choice when an aminoglycoside
is required. Amikacin and, especially, netilmicin appear to be
less nephrotoxic therapeutic alternatives to gentamicin and
tobramycin, but these should be reserved for bacterial strains
resistent to gentamicin and tobramycin. In contrast to amika-
cm, netilmicin is associated with substantially less cochlear and
vestibular toxicity [30]. I should emphasize that the choice of an
aminoglycoside antibiotic depends on the patient, clinical set-
ting, local bacterial resistance patterns, and importantly, on
culture and sensitivity results when these are available, because
all aminoglycosides have the potential for producing nephro-
toxic complications.
Patho genesis
Rena! aspects. The final common pathogenetic pathway for
the development of either ischemic or nephrotoxic acute renal
failure is renal tubular cell injury [31]. Progressive renal tubular
cell injury initiates alterations at the nephronal level that
ultimately result in renal insufficiency. These alterations in-
clude: (I) intratubular obstruction, (2) backleak of glomerular
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filtrate through damaged tubular epithelium, and (3) reduction
in glomerular filtration rate of solute and water. Of these three
factors, intratubular obstruction appears to be a major mecha-
nism for a decline in glomerular filtration rate (GFR) in both
ischemic and nephrotoxic acute renal failure. Recent studies
have shown that if the intraluminal blockage to urine flow is
diffuse enough to involve most functioning nephrons, this
process will lead to a major decline in renal excretory function
[31. 32]. Free-flow micropuncture studies of experimental ami-
noglycoside nephrotoxicity show that all functioning nephrons
had elevated intratubular pressures compared with controls
[30]. Single-nephron GFR (SNGFR) was diminished in involved
tubules compared with controls and rose as intratubular pres-
sure was decreased. Microinfusion of involved tubules led to
marked increases in intranephronal pressures. Elevations of
intratubular pressures in controls to levels observed in drug-
treated rats led to reductions in SNGFR to levels observed in
injured tubules.
The necrotic cells shed into the tubular lumen not only reduce
renal excretory function by obstructing urine flow but also by
leaving gaps along the tubular epithelia through which glomer-
ular filtrate can re-enter the circulation. With this disruption,
the effective GFR is compromised further. Recent studies.using
microinjection techniques have correlated the magnitude of
backleak with the extent of severe tubular injury present in
acute tubular necrosis (ATN) [32].
The GFR also might decline in acute tubular necrosis because
of primary disturbances in the glomerular filtration process. The
reduction could be due to a fall in glomerular capillary hydro-
static pressure or renal blood flow, or to a decrease in the
glomerular capillary ultrafiltration coefficient, K1 [33J. The K is
a function of the permeability of the glomerular capillary wall to
water and of the surface area available for filtration. Substantial
evidence has demonstrated that the intrarenal generation of the
vasoconstrictor hormone angiotensin II (All) dramatically low-
ers both renal blood flow (from renal arteriolar contraction) and
Kf (from mesangial cell contraction); these decreases lead to a
reduction in glomerular capillary surface area [331. In principle,
both alterations could diminish GFR. Despite much study,
however, a definitive role for alterations in renal blood flow in
the initiation or maintenance of nephrotoxic acute renal failure
has not been established. Manipulations of the renin-angioten-
sin system have not yielded evidence of a role for this hormone
system in acute tubular necrosis. In this regard, the increase in
All generation in the kidney is thought to represent a secondary
derangement of lesser importance arising from the primary
process of renal tubular cell injury. The improvement of this
secondary change in GFR does not ameliorate the underlying
primary tubular injury, and therefore any All-mediated changes
in glomerular hèmodynamics early in the process of renal cell
injury would be expected to be far overshadowed by the GFR
decline prompted by intratubular obstruction and backleak.
Micropuncture studies have delineated several alterations in
the determinants of glomerular ultrafiltration in gentamicin
nephrotoxicity in particular. Doses of gentamicin that did not
produce severe tubular cell injury led to modest declines in
GFR in the rat. The primary cause for this reduction in GFR
was a significant decline in Kç, although a small decline in
glomerular plasma flow was noted in the experimental group
given high doses. This decline in plasma flow contributed to the
decreased SNGFR 1341. Other data show that the angiotensin-
converting enzyme inhibitor captopril almost completely pre-
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vents the untoward effects of gentarnicin on glomerular hemo-
dynamics [35]. Although these results are compatible with the
hypothesis that gentamicin-jnduced functional derangements in
glomerular hemodynamics are secondary to increased intrare-
nal angiotensin II generation, 3 days of captopril treatment
preceded this study. The possibility exists, therefore, that other
determinants of nephrotoxicity, such as tissue drug concentra-
tion, are at play. in fact, further studies using gentamicin doses
that produced both functional and morphologic evidence of
severe renal failure demonstrated that captopril treatment or
pretreatment did not ameliorate renal functional, morphologic,
or glomerular ultrastructural features of aminoglycoside neph-
rotoxicity [36]. The results of this study argue against a domi-
nant role for the renin-angiotensin system in severe renal failure
induced by aminoglycosides.
Cellular aspects. Any comprehensive view of the pathogen-
esis of acute tubular necrosis requires an explanation of the
biochemical alterations responsible for the loss of renal tubule
cell integrity. Without tubule cell injury, the various factors
responsible at the nephronal level for renal failure would not be
initiated. Growing evidence suggests that nephrotoxins and
ischemia exert their primary detrimental effects on cells by
disturbing the membranes of the cell [30]. Both the plasma
membrane and the intracellular organellar membranes are po-
tential sites of toxicity. Because of the transport properties of
the renal tubular cell, its membranes are especially susceptible
to toxic insult. The transport of a multiplicity of compounds
through the intracellular matrix of the renal tubular cell exposes
the membranes of its subcellular organdies, such as the mito-
chondnal inner membrane, to potentially toxic concentrations
of a variety of substances. In addition, because the renal tubule
avidly reabsorbs salt and water, substances are concentrated
within the tubular lumen, thereby exposing the luminal mem-
branes of renal tubular cells to potentially toxic concentrations.
These membrane alterations in the renal tubular cell produce
multiple biochemical derangements that ultimately lead to cell
death. We are only now beginning to clarify the manner of
interaction and the rank order of importance of the multiple
biochemical abnormalities that are initiated by either toxins or
ischemia.
Most recent studies have focused on the manner in which
these antibiotics interact with the plasma membrane of the renal
tubular cell and the important subcellular organeliar mem-
branes, primarily those of the mitochondria and the lysosomes.
Investigation of the physiochemical nature of aminoglycoside-
membrane interactions, both in vivo and in vitro, led us to
identify acidic phospholipids as the molecular sites for amino-
glycoside binding [371. Other investigations also have demon-
strated global alterations in phospholipid metabolism and asso-
ciated alterations in the lipid content of plasma and organellar
membranes, altered plasma-membrane-bound enzyme activi-
ties, and disturbances in organellarfunction[l3]. The scope and
implications of these findings as summarized in Table 2 will be
briefly considered.
Plasma membrane. Binding between aminoglycosides and
membrane phospholipids appears to involve the electrostatic
interaction of the cationic, polybasic antibiotic and the acidic
phospholipids, particularly the phosphoinositides [37, 38]. A
role for less-well-defined acidic phospholipid moieties in mem-
brane binding has not been excluded, however [38]. Competi-
Table 2. Membrane alterations in aminoglycoside nephrotoxicity
Plasma membrane alterations
1. Phospholipid alterations: aminoglycoside binding to membrane
acidic phospholipids; changes in content and metabolism of mem-
brane phospholipids; displacement of Ca + bound to phospholip-
ids
2. Transport defects: inhibition of Na-K-ATPase and adenylate cy-
clase; alterations in PAH transport; renal wasting of K and Mg*+
Mitochondrial membrane alterations
1. In-viva gentamicin: decreased State 3 and DNP-uncoupled respira-
tion
2. In-vitro gentamicin: increased State 4, decreased State 3. and
DNP-uncoupled respiration secondary to alteration of Mg-con-
trolled, monovalent cation permeability pathway; inhibition of
Ca transport
Lysosomal membrane alterations
I. Lysosomal instability, in vitro and in vivo
2. Diminished phospholipase activity
tive binding studies of brush-border membrane vesieles and
liposomes with various aminoglycosides and polyamines lend
further support for a predominant role of anionic phospholipids
in drug binding [37, 39]. Study of in-vitro drug binding interac-
tions, however, fails to completely predict whole-organ neph-
rotoxicity [31]. Stepwise computer conformational analyses of
aminoglycoside-phospholipid bilayer systems have suggested
that hydrophobic interactions and lipid bilayer penetration are
potentially important modifiers of simple electrostatic binding
[40]. Such sophisticated physical approaches might provide
greater insight into the biochemical mechanisms of aminoglyco-
side nephrotoxicity, the creation of less nephrotoxic drugs, and
an explanation for the failure of simple electrostatic formula-
tions to predict binding and toxicity.
Immediate and strong aminoglycoside-phospholipid binding
characterizes the interaction of these drugs with the kidney.
The resulting membrane alterations therefore might figure im-
portantly in the pathogenesis of aminoglycoside-induced acute
renal failure. Specific alterations in cellular phospholipids occur
in whole-animal, human, and cell-culture models of amino-
glycoside nephrotoxicity [31]. Available evidence suggests that
these lipid compositional alterations involve all cellular organ-
elles and probably result from drug inhibition of multiple
phospholipases of varying substrate specificity and cellular
location as well as from redirection of glycerolipid biosynthesis
[41, 42]. Although a precise causal relationship between cellular
phospholipidosis and injury has not yet been demonstrated,
evidence linking cellular phospholipidosis to organ injury has
been adduced in several models of drug toxicity involving
cationic compounds [43].
Several tubular cell membrane functional changes occur with
aminoglycoside exposure. The activity of sodium-potassium
ATPase, the major regulator of the cation gradients across
plasma cell membranes, critically depends on its surrounding
phospholipid environment [44]. Neomycin inhibits sodium-
potassium ATPase activity in vitro, and this effect is specifically
antagonized by phosphatidylinositol [45]. Administration of
large doses of gentamicin results in significant and reversible
declines in sodium-potassium ATPase activity in vivo [46].
Persistent decreases occur as a late effect and might he related
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Fig. 2. In-vitro and in-vivo dose responses of polyamino acid inhibition
of membrane binding and nephrotoxicity of gentamicin. A refers to
polyasparagine membrane-binding inhibition: refers to polyaspara-
gine nephrotoxicity inhibition; • refers to polyaspartic acid membrane-
binding inhibition; and 0 refers to polyaspartic acid nephrotoxicity
inhibition. These data demonstrate that these polyamino acids both
inhibit gentamicin binding to isolated renal brush-border membranes
and protect against gentamicin nephrotoxicity at similar molar ratios.
Reprinted from Ref. 77.
to generalized membrane deterioration. The activity of the
membrane-bound enzyme adenylate cyclase also has been
shown to depend on its phospholipid environment [47]. Amino-
glycoside exposure inhibits fluoride-stimulated adenylate cy-
clase of rat proximal tubular basolateral membrane in vivo and
inhibits toad bladder adenylate cyclase in vitro [19, 48]. Ami-
noglycosides also have selective effects on the organic acid
secretory transport process. Gentamicin treatment increases
both renal clearance of para-aminohippurate (PAH) and renal
slice uptake of PAH: the latter effect was observed after a single
dose [49], Both PAH transport and organic base transport
decline at later stages of nephrotoxicity; this fall probably is a
nonspecific effect of progressive renal cell injury.
Considerable evidence indicates that aminoglycosides are
presented to the tubular cell in high concentrations, leading to
phospholipid binding and subsequent alterations in cell phos-
pholipid composition. Additionally, these antibiotics provoke
early and specific alterations in plasma membrane permeability
and transport, many of which are mediated by membrane
phospholipid binding and alterations. While the resulting changes
in the intracellular environment can have indirect detrimental
effects on intracellular processes and organellar function, addi-
tional data have demonstrated aminoglycosides' potential for
altering organellar membranes directly.
Alterations in organellar structure and function. Intact mito—
chondrial oxidative phosphorylation is essential to the mainte-
nance of normal renal tubular cell function. 'I'he capacity of the
mitochondrial membrane for oxidative phosphorylation and its
associated cation and anion transport process is thus a complex
integrated function, depending on both the integrity and limited
cation permeability of that membrane and the stability of the
intracellular environment. Given the transporting and concen-
trating properties of the renal tubular epithelium, substantial
opportunity exists for the membrane-active aminoglycosides to
affect bioenergetics. These effects occur both by means of
direct effects on the mitochondrial membrane as well as by
means of alterations in the intracellular environment because of
effects on other cellular membranes. These alterations in renal
cell bioenergetics probably contribute importantly to the patho-
genesis of cell injury produced by the aminoglycoside antibiot-
ics.
The aminoglycosides have specific and reversible effects at
the inner mitochondrial membrane, where membrane-bound
magnesium plays a critical role in the regulation of membrane
transport processes. Gentamicin competes with magnesium for
membrane sites, where magnesium limits membrane permeabil-
ity to monovalent cations. Gentamicin itself, however, is not as
effective as magnesium in limiting monovalent cation perme-
ability. This effect results in mitochondrial swelling and alter-
ations in mitochondrial respiratory function [50, 51]. Other
aminoglycoside antibiotics have mitochondrial effects similar to
those produced by gentamicin with a relative potency that
correlates with their cationicity [52]. Magnesium also acts at the
inner mitochondrial membrane to limit mitochondrial calcium
uptake. In this case, the effects of gentamicin are additive to the
effects of magnesium on calcium uptake [53]. These alterations
in mitochondrial membrane alterations appear to relate, at least
in part, to aminoglycoside-induced stimulation of the generation
of reactive oxygen metabolites by renal cortical mitochondria
[54].
Aminoglycosides also have well-defined effects on lysosomal
membranes in vitro. Aminoglycosides inhibit the activity of
lysosomal phospholipases A and C from renal cortex [55. 561.
At low concentrations, aminoglycosides, as a function of their
cationicity, stabilize isolated lysosomes, whereas at high con-
centrations they increase lysosomal lability [57].
These effects of aminoglycosides on subcellular membranes
also appear to occur in vivo [60]. Data are available on the
in-vivo effects of gentamicin in a number of subcellular sys-
tems. To gain insight into pathogenetically important processes,
it is important that attention be given to phenomena that occur
prior to massive cell necrosis and disruption. Mitochondria
isolated from rats treated with gentamicin are functionally
abnormal prior to severe tubular cell injury as compared with
controls [58]. However, the pattern of mitochondrial functional
effects seen after in-vivo gentamicin administration differs from
that seen with in-vitro exposure. Thus it is difficult to say with
certainty whether the in-vivo effects are due to direct interac-
tions of gentamicin with mitochondria or are secondary to
another early intracellular process evoked by gentamicin. In
either case, function of this vital intracellular organelle is
compromised early enough during the course of aminoglycoside
exposure to potentially contribute to the pathogenesis of renal
cell injury. Although nephrotoxin-related alterations in renal
cell bioenergetics appear to be a potential, common biochemi-
cal pathway in the pathogenesis of nephrotoxic acute renal
failure [59]. current evidence does not assign mitochondrial
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dysfunction a unique role in the early pathogenesis of amino-
glycoside nephrotoxicity. Important questions remain.
Lysosomal alterations occur soon after exposure of renal
tubule cells to aminoglycosides. Lysosomes within proximal
tubule cells increase in size and number, and lysosomal enzym-
uria occurs [11], accompanied by increases in renal cortical
content of at least one lysosomal enzyme, NAG [42]. Lysoso-
mal enzyme activity, including sphingomyelinase and phospho-
lipase A from renal cortex, is inhibited early in the course of
experimental aminoglycoside nephrotoxicity [60, 611. Both drug-
induced lysosomal alterations (with resulting impairment in
membrane degradation and recycling) and toxic lipid sequestra-
tion (with subsequent release of lysosomal enzyme contents)
might contribute to the pathogenesis of renal cell injury. Al-
though it currently is impossible to ascribe a predominant
pathogenetic role to any one aminoglycoside-induced mem-
brane or organellar impairment in the causation of renal failure,
these differing adverse organellar effects probably are closely
interrelated in the pathogenesis of aminoglycoside nephrotox-
icity.
Clinical determinants. Clearly, a structural component of the
aminoglycosides imparts toxic potential to these compounds.
Recent evidence supports the thesis that the cationicity derived
from ionizable amino groups is a major molecular determinant
of aminoglycoside membrane action. The toxic potential of an
aminoglycoside antibiotic is attributable in large part to its
ability to interact with membranes and to alter membrane
structure and function. It is therefore not surprising that a rough
correlation between cationicity and whole-organ toxicity exists
[31]. A single group of aminoglycosides with identical cationic
changes, however, can have appreciable differences in toxicity
[62]. In fact, more refined analyses of aminoglycoside-mem-
brane interactions have suggested significant effects on binding
by amino-group orientation and by hydrophobic interactions
[40].
Nonetheless, there is little doubt that the cationic amino
groups are the structural determinants of toxicity. Polydis-
persed neutral dextran consists of linearly branched chains of
glucose residues connected by glycosidic linkages of varying
molecular size. This compound has no nephrotoxic activity or
deleterious effects on mitochondrial membrane function. The
addition of cationic diethylaminoethyl (DEAE) substitution
groups to the glucose residues of neutral dextran yields a
preparation of DEAE dextran remarkably reminiscent of the
structure of the aminoglycoside antibiotics. This compound has
substantial nephrotoxicity, producing severe necrosis in S1 and
S2 segments of the proximal tubule within 48 hours after
administration [63]. In fact, a variety of low-molecular-weight
organic compounds that possess significant cationic charge
density derived from ionizable amino groups can induce irre-
versible cell injury [31].
Modification of experimental a,ninoglvcoside nephrotoxicitv
Numerous conditions modify both the time course and sever-
ity of experimental aminoglycoside nephrotoxicity. As I noted
earlier, these factors include the animal's age, gender, species
and strain, and the aminoglycoside dose and dosing interval
[31]. Within a well-defined experimental setting, various sys-
temic and renal alterations also have been demonstrated to
modulate aminoglycoside nephrotoxicity (Table 3). These in-
Table 3. Modification of experimental aminoglycoside nephrotoxicity
Potentiating factors
I. Hypercalcemia
2. Potassium depletion
3. Magnesium depletion
4. Metabolic acidosis
5. Endotoxemia
6. Pyelonephritis
Protective factors
1. Uncontrolled streptozotocin-induced diabetes mellitus
2. Parathyroidectomy
3. Thyroxine administration
4. Phosphate depletion
5. Oral calcium supplementation
6. Polyamino acid administration
dude alterations in phosphorus and divalent cation intake or
renal handling, potassium or magnesium deficiency, hypercal-
cemia, metabolic acidosis, the presence of uncontrolled diabe-
tes mellitus, hypothyroidism, parathyroid hormone deficiency,
pyelonephritis, and endotoxemia. These observations regarding
modulation of nephrotoxicity are important, because they might
provide insights into the pathogenesis of renal cell injury and
could have important implications for the prevention of clinical
aminoglycoside-induced acute renal failure.
Uncontrolled streptozotocin-induced diabetes mellitus in the
rat protects against gentamicin-induced acute renal failure [64].
This effect can be observed as early as 5 days after streptozo-
tocin treatment and is uniformly associated with renal cortical
aminoglycoside levels lower than in controls. Although the
precise mechanism of protection remains obscure, elevated
GFR and decreased renal cortical drug binding sites, with
resulting diminished cortical drug accumulation, seem to be
important [65]. A partial role for solute diuresis and urine flow
rate also seems likely.
Treatment with thyroxine of normal and parathyroidectom-
ized rats prevents aminoglycoside-induced alterations in renal
function [66]. This protective effect of thyroxine could not be
explained by alterations in GFR or calcium excretion. The
activity of renal cortical sodium-potassium ATPase, however,
correlated with total plasma thyroxine in both control and
gentamicin-treated animals. This protective effect of thyroxine
lacks specificity and has been observed both in ischemic renal
failure and in other models of nephrotoxicity [67]. Parathyroid-
ectomy in Fisher 344 rats fed a standard diet conferred partial
protection from aminoglycoside nephrotoxicity compared with
sham-operated controls [68]. Another study, however, did not
report a protective effect from parathyroidectomy on amino-
glycoside nephrotoxicity in rats [66].
Electrolyte alterations also modulate aminoglycoside neph-
rotoxicity. Aluminum hydroxide-induced phosphorus depletion
ameliorates gentamicin nephrotoxicity in the rat [69], and acute
phosphate infusion causes both functional and morphologic
worsening of ischemic acute renal failure [70]. Production of
mild hypercalcemia with I ,25(OH)D1 markedly potentiates the
severity of aminoglycoside nephrotoxicity [71]. Experimental
magnesium deficiency promotes aminoglycoside nephrotoxicity
in Sprague-Dawley rats [27]. Studies in rodents and dogs clearly
demonstrate that hypokalemiaexacerbates aminoglycoside neph-
rotoxicity [261. Metabolic acidosis significantly worsens genta-
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micin-induced acute renal failure in the rat [72]. Renal infection
or systemic infection complicated by endotoxemia potentiates
aminoglycoside nephrotoxicity [73]. This potentiation is due, at
least in part, to more rapid accumulation of aminoglycosides in
renal parenchyma.
The mechanisms by which these renal or systemic factors
alter aminoglycoside nephrotoxicity are not well understood.
Most are likely nonspecific and probably affect other forms of
nephrotoxic injury as well. Those factors that specifically
influence aminoglycoside nephrotoxicity appear to act by in-
creasing the rate of antibiotic accumulation within the renal
cortex.
Approaches that may ameliorate aminoglycoside nephrotox-
icity are promising. Among these attempts, the most exciting
consists of identifying compounds that are competitive inhibi-
tors of aminoglycoside membrane binding. Small organic poly-
cations were initially tested, but these had appreciable nephro-
toxicity of their own [74]. Because calcium is an effective
competitive inhibitor of aminoglycoside binding to biologic
membranes [75], oral calcium supplementation was used to
increase delivery of the ion to the kidney. Oral calcium loading
markedly protected against gentamicin nephrotoxicity as mea-
sured by both renal functional and biochemical indices of renal
cell injury [75, 76]. However, the protective effect of calcium
was not accompanied by a change in either peak renal cortical
gentamicin levels or the time taken to reach them. Thus it is
possible that the effects of calcium are mediated either by the
inhibition of gentamicin's action within renal cells rather than
on their surfaces, or another metabolic alteration might occur
during oral calcium loading. Because of the large amounts of
calcium required to achieve this protective effect, this maneu-
ver probably is not clinically applicable.
This type of therapeutic approach has been extended to the
use of various polyamino acids, including polylysine, polyaspa-
ragine, and polyaspartic acid [77]. These compounds inhibit
aminoglycoside binding to renal brush-border membranes. Fur-
thermore, these agents, when coadministered with aminoglyco-
sides to rats, completely protect against nephrotoxicity but
have no effect on the antibacterial activity of these antibiotics in
vitro [77]. These findings demonstrate that we can identify
interventions for ameliorating nephrotoxicity as soon as we
understand the cellular pathophysiology of the toxic process.
Now let us return to the patient presented today. The initial
decrease in the patient's renal function on admission was the
result of the volume depletion as evidenced by the normal
urinalysis, low UNa, and high urine osmolality. The subsequent
decrease in renal function 6 days after operation was caused by
acute tubular necrosis induced by gentamicin, as reflected by
the abnormal urinalysis, high UNa and FENa, and low urine
osmolality. Acute tubular necrosis occurred despite the use of a
"normal" dose of gentamicin, probably because of the patient's
age and the coexisting volume depletion. These factors should
have prompted different therapeutic choices and clinical follow-
up: euvolemia should have been aggressively maintained through-
out the patient's course. Because the patient was elderly,
tobramycin rather than gentamicin should have been used.
Serum gentamicin levels should have been measured on the first
and second days after therapy was begun so that dose adjust-
ments could have been made as appropriate rather than 6 days
into the patient's course, when the serum creatinine level was
first noted to be elevated. Furthermore, BUN and serum
creatinine should have been monitored daily.
The serum creatinine followed a typical triphasic pattern: a
rapid increase, a gradual plateau, and a slow to moderate
improvement to normal. As I noted before, a continued in-
crease in serum creatinine after discontinuation of the antibiotic
is common, because renal cell injury continues when toxic
concentrations of the drug persist in the renal parenchyma.
Fortunately, the nonoliguric state helped maintain normokale-
mia and volume homeostasis without uremic symptoms, and
dialysis was not required.
Questions and answers
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partinent of Medicine, Nest' England Medical Center, Boston,
Massachusetts): How important is the cationic nature of the
aminoglycosides with respect to their effect on bacteria? If you
interfere with one effect, you might, in principle at least,
interfere with the other.
DR. HUMES: The cationicity of the aminoglycosides probably
dictates their membrane interactions with bacterial membranes
as well as their transport into bacteria. Thus, the cationicity of
these antibiotics also is an important determinant for their
antimicrobial activity. Of note, the report using large-molec-
ular-weight polyamino-substituted derivatives demonstrated a
protective effect on aminoglycoside nephrotoxicity but did not
alter the antimicrobial activity of aminoglycosides in vitro [77].
This dissociation might relate to the large size of the polyamino-
substituted derivative.
DR. MICHAEL BARZA (Division of Geographic Medicine and
Infectious Diseases, New England Medical Center): Gram-
negative bacteria have an outer membrane containing pores
through which most substances that are not highly lipid-soluble
must pass in order to enter the cytoplasm. Large molecules
such as the ones you are describing would be unlikely to pass
through the outer membrane.
DR. HUMES: Your explanation appears very reasonable.
DR. KASSIRER: Is there any effect of these large cationic
molecules on other cells or organs? I ask this question because
of the extent of anionic sites in various glycoproteins and other
structural proteins throughout the body. Is there evidence of
toxicity in these tissues?
DR. HUMES: I am not aware of potential toxicity of these
agents on other tissues.
DR. BARZA: Aminoglycosides only appear to be concentrated
in two sites inthe body: the proximal renal tubule and the inner
ear. Those are the only two sites that seem to have these
polyphosphoinositol substances that act as receptors for ami-
noglycosides. It may be that, like aminoglycosides, other poly-
cationic substances fail to be taken up by most tissues of the
body.
Some years ago. we studied proximal tubular preparations
and showed that the uptake of radiolabeled gentamicin ap-
peared to he inhibited by 2,4-dinitrophenol and cold tempera-
tures. This finding suggested an active transport system. Did
you allude to that?
DR. HUMES: No, I did not allude to that phenomenon,
Aminoglycosides are taken up by proximal tubule cells via an
endocytotic process, which is an energy-dependent process.
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Thus this transport process is influenced by maneuvers that
interrupt energy transduction processes.
Da. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center): You indicated that pretreatment of
rats with calcium ameliorated aminoglycoside-induced acute
renal failure. Have you looked further at magnesium or other
physiologic cations in similar circumstances?
DR. HUMES: Yes, we initially studied magnesium supplemen-
tation. This maneuver, however, resulted in severe diarrhea in
the animals, as well as subsequent volume depletion and
electrolyte imbalances. These disturbances would alter the
development of aminoglycoside-induced renal dysfunction and
obscure the final results. We therefore undertook the studies
using calcium supplementation.
DR. JOHN T. HARRINGTON: (Chief of Medicine, Newton-We!-
lesley Hospital, Newton, Massachusetts): I would like to follow
up on Dr. Perrone's question. Does calcium protect against
gentamicin nephrotoxicity at a luminal site or at an intracellular
site?
DR. HUMES: The animals that were given oral calcium
supplements developed hypercalciuria but not hypercalcemia. I
therefore would speculate that the protection develops from a
luminal membrane event. Oral calcium supplementation also
produces other alterations such as hypophosphatemia, which
might ameliorate aminoglycoside toxicity by other mechanisms
separate from competitive inhibition of membrane binding.
DR. HARRINGTON: Given that calcium's protection against
aminoglycoside nephrotoxicity seems to be on the luminal side,
what do you think mediates the effect of volume depletion in
promoting gentamicin toxicity? Is it a sodium-dependent phe-
nomenon or might it be calcium dependent as well?
DR. HUMES: The routine answer has always been that volume
depletion leads to increased concentration of aminoglycosides
in the renal cortex, but aminoglycoside transport by renal
epithelia is not a sodium-dependent process. Instead, I think
this potentiation might relate to the influence of volume deple-
tion on renal blood flow. It's been shown that brief renal
ischemia potentiates nephrotoxic injury [78].
DR. NIcOLAOs E. MADIAS (Chief, Division of Nephrology,
New England Medical Center): In some studies, metabolic
acidosis has been shown to potentiate aminoglycoside nephro-
toxicity. I noted that in your calcium protective studies you
used calcium carbonate; is it possible that part of the protection
actually derived from the administered alkali load?
DR. HUMES: These studies incorporated a group of animals
that were supplemented with equivalent amounts of sodium
bicarbonate to calcium carbonate. Sodium bicarbonate supple-
mentation was not protective.
Da. JAMES STROM (Chief, Division of Nephrology, St. Eli-
zaheth's Hospital, Boston): What is the link between the
aminoglycosides' polycationic membrane interaction and the
displacement of magnesium?
DR. HUMES: Magnesium and calcium are bound to all cellular
membranes and are important in the regulation of various
transport processes.
DR. STROM: And is this caused specifically by the polycati-
onic interaction?
DR. HUMES: The displacement of these divalent cations by
the aminoglycoside antibiotics produces membrane dysfunc-
tion, at least in part, by this effect.
DR. STROM: And a clinical question: Wouldn't it be unwise to
measure aminoglycoside levels on the first day, before steady-
state levels have been achieved?
DR. HUMES: It is best to measure aminoglycoside levels after
a steady state has been achieved. The point I would like to
make is that this measurement should be done after 24 or 48
hours following initiation of aminoglycoside therapy rather than
after 5 days.
DR. VINCENT J. CANZANELLO (Division ofNephrology, New
England Medical Center): Many of our patients have preexist-
ing renal disease. When we give aminoglycosides to these
patients, how should we administer the drug?
DR. HUMES: Preexisting renal insufficiency probably is a risk
factor for any nephrotoxin, because of an increase in delivery of
the potential nephrotoxin per functioning nephron. For ami-
noglycosides, animal studies have demonstrated that for any
given total dose, adjustments downward in dose are more
nephrotoxic than are adjustments upward in dosing intervals
[79]. Other studies, however, suggest that better antimicrobial
efficacy is accomplished with dose adjustments rather than with
dosing interval alterations. The final decision therefore will
depend on the individual clinical situation and the risk/benefit of
either approach.
DR. MADIAS: How good is the correlation between antibiotic
blood levels and nephrotoxicity in animal and clinical studies?
DR. HUMES: There is only an approximate correlation, The
problem is that a variety of factors can influence the patient's
risk of developing nephrotoxicity. If the patient is septic and
volume depleted, aminoglycoside toxicity still can develop, no
matter how well the physician controls the serum levels.
Da. MADIAs: Is there any clinical utility for monitoring the
enzymuria associated with the onset of aminoglycoside neph-
rotoxicity?
DR. HUMES: No. Enzymuria is nonspecific and too sensitive
a marker to be diagnostically or prognostically beneficial.
DR. KASSIRER: Some evidence was presented several years
ago that aminoglycosides produce a reduction in K1. Given the
huge amount of polyanions in the glomerular capillary wall and
particularly in the basement membrane, does a reduction in Kf
contribute to the reduction in GFR in gentamicin nephrotoxic-
ity?
DR. HUMES: As I mentioned, arninoglycosides produce a
modest decline in K1. This decline is not the predominant cause
of the decline in renal excretory function. The predominant
pathophysiologic process is the toxic injury to the proximal
tubule cell produced by the aminoglycoside.
D. PERRONE: Although there is no accepted role for diuret-
ics in the prevention of acute renal failure, can you envision any
point in this process at which a diuretic might have an impact in
a mechanistic way to prevent either uptake or binding of an
aminoglycoside?
D. HUMES: No; in fact, aggressive diuresis can aggravate
the potential nephrotoxicity because of the resulting volume
depletion and potassium depletion.
DR. KASSIRER: How often does aminoglycoside nephrotox-
icity produce permanent renal failure?
DR. HUMES: Like most toxic injury to the kidney, it is a
reversible process because of the regenerative ability of the
renal epithelium to reline the tubule. Interstitial fibrosis can
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develop after nephrotoxicity, however, hut not sufficiently to
cause renal insufficiency.
D, KASSIRER: Given the mechanisms you proposed for the
initiation of acute renal failure by aminoglycosides, I do not
understand the mechanism of the recovery. If obstruction and
backleak are the major factors, the repair of the tubular
epithelium should result in a reduced backleak and a greater
quantity of fluid remaining in the tubule in the presence of
continued obstruction. If anything, the retrograde pressure on
the glomerulus would increase and GFR would fall further. Do
we know anything about how obstruction is relieved and about
the relation between relief of obstruction and reduction in
tubular backleak?
DR. HUMES: No one has carefully looked at the recovery
phase of acute renal failure either from a micropuncture or a
biochemical approach. This recovery phenomenon is an area
waiting to be explored.
DR. MADIAS: I believe there are some good data suggesting
that the recovery process of aminoglycoside nephrotoxicity can
express itself in the presence of continued exposure to the
antibiotic. Is there an understanding of this phenomenon?
DR. HUMES: Studies have demonstrated that renal epithelia
during the recovery phase of nephrotoxic injury are resistant to
a subsequent toxic event [80]. Aminoglycosides are a clear
example of this phenomenon. The explanation for this process
currently is not understood, but it might relate to the resistance
of immature, regenerating renal epithelial cells to toxic injury.
DR. HENRY YAGER (Associate Chief of Medicine, Newton-
Wellesley Hospital): In clinical practice, we often use aminogly-
cosides in combination with other antibiotics. The literature has
some conflicting data about the synergistic effect of cephalo-
sporins on aminoglycoside toxicity. Could you comment on
that?
DR. HUMES: Two cephalosporins seem to potentiate amino-
glycoside nephrotoxicity: cephaloridine and cephalothin. The
newer cephalosporins fortunately do not appear to have this
ability.
Reprint requests to Dr. H. D. Humes. Medical Service, Veterans
Administration Medical Center, 22/5 Fuller Road, Ann Arbor, Michi-
gan 48105, USA
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